Stanford researchers at the Lee Lab have developed a new system and method for measuring pathology then applying a novel algorithm to optimize neurostimulation therapy for altering pathology for treatment of neurodegenerative diseases.
Stanford researchers at the Lee Lab have developed a method to understand whole-brain circuit mechanisms underlying neurological disease and its application to predict the outcome of therapeutic interventions.
Stanford researchers from the Khuri-Yakub group have designed an improved, high spatial resolution ultrasonic neuromodulation device that implements chip waveform instead of continuous wave PIRF.
A common hurdle for many drug delivery applications is getting the desired compounds to the targeted cells or receptors. Additional barriers of achieving the therapeutic drug concentration and necessary drug diffusion are also present even after successful targeted delivery.
Researchers in the laboratories of Dr. Karl Deisseroth and Dr. Peter Hegemann have engineered mutant ChR2 (Channelrhodopsin-2) proteins with light-sensitivity that is increased by orders of magnitude compared to wild-type ChR2.
Researchers in Prof. Karl Deisseroth's lab have discovered and engineered new microbial opsin proteins and cell trafficking tools to enable selective cell-type specific, light-sensitive switches for neuromodulation.
Researchers from Prof. Karl Deisseroth's laboratory have developed techniques for specifically modulating the activity of excitable cells in vivo. This approach introduces light-responsive proteins to create photo-sensitive cells.
The inventors have developed a light-driven chloride pump (NpHR or Halo) for temporally precise optical inhibition of neural activity with ordinary yellow light.